Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?

Aslanidi GV, Rivers AE, Ortiz L, Song L, Ling C, Govindasamy L, Van Vliet K, Tan M, Agbandje-McKenna M, Srivastava A.

PLoS One. 2013;8(3):e59142. doi: 10.1371/journal.pone.0059142. Epub 2013 Mar 19.

2.

Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R, Samuel R, Srinivasan N, Srivastava A, Jayandharan GR.

Hum Gene Ther Methods. 2013 Apr;24(2):80-93. doi: 10.1089/hgtb.2012.194. Epub 2013 Mar 15.

3.

Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.

Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, Samuel R, Rajalingam S, Ramya V, Nair SC, Srinivasan N, Srivastava A, Jayandharan GR.

Hum Gene Ther Methods. 2013 Apr;24(2):104-16. doi: 10.1089/hgtb.2012.195.

4.

Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo.

Li B, Ma W, Ling C, Van Vliet K, Huang LY, Agbandje-McKenna M, Srivastava A, Aslanidi GV.

Hum Gene Ther Methods. 2015 Dec;26(6):211-20. doi: 10.1089/hgtb.2015.115. Epub 2015 Oct 27.

5.

Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.

Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH Jr, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A.

Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7827-32. doi: 10.1073/pnas.0802866105. Epub 2008 May 29. Erratum in: Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):11032.

6.

High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines.

Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L.

Mol Ther. 2010 Dec;18(12):2048-56. doi: 10.1038/mt.2010.172. Epub 2010 Aug 24.

7.
8.

High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy.

Li M, Jayandharan GR, Li B, Ling C, Ma W, Srivastava A, Zhong L.

Hum Gene Ther. 2010 Nov;21(11):1527-43. doi: 10.1089/hum.2010.005. Epub 2010 Oct 6.

9.

Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.

Jayandharan GR, Zhong L, Sack BK, Rivers AE, Li M, Li B, Herzog RW, Srivastava A.

Hum Gene Ther. 2010 Mar;21(3):271-83. doi: 10.1089/hum.2009.100.

10.

High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.

Aslanidi GV, Rivers AE, Ortiz L, Govindasamy L, Ling C, Jayandharan GR, Zolotukhin S, Agbandje-McKenna M, Srivastava A.

Vaccine. 2012 Jun 6;30(26):3908-17. doi: 10.1016/j.vaccine.2012.03.079. Epub 2012 Apr 10.

11.

Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.

Jayandharan GR, Zhong L, Li B, Kachniarz B, Srivastava A.

Gene Ther. 2008 Sep;15(18):1287-93. doi: 10.1038/gt.2008.89. Epub 2008 May 22.

PMID:
18496572
12.

Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction.

Naumer M, Popa-Wagner R, Kleinschmidt JA.

J Gen Virol. 2012 Oct;93(Pt 10):2131-41. doi: 10.1099/vir.0.044735-0. Epub 2012 Jul 4.

PMID:
22764318
13.

A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis.

Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, Govindasamy L, Agbandje-McKenna M, Srivastava A.

Mol Ther. 2007 Jul;15(7):1323-30. Epub 2007 Apr 17.

14.

Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site.

Huang LY, Patel A, Ng R, Miller EB, Halder S, McKenna R, Asokan A, Agbandje-McKenna M.

J Virol. 2016 May 12;90(11):5219-30. doi: 10.1128/JVI.00161-16. Print 2016 Jun 1.

15.

Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Boye SL, Bennett A, Scalabrino ML, McCullough KT, Van Vliet K, Choudhury S, Ruan Q, Peterson J, Agbandje-McKenna M, Boye SE.

J Virol. 2016 Mar 28;90(8):4215-31. doi: 10.1128/JVI.00200-16. Print 2016 Apr.

16.

Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression.

Zhong L, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW, Weigel-Van Aken KA, Hobbs JA, Zolotukhin S, Muzyczka N, Srivastava A.

Virology. 2008 Nov 25;381(2):194-202. doi: 10.1016/j.virol.2008.08.027. Epub 2008 Oct 2.

17.

Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.

Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, Ostrov DA, Srivastava A, Ertl HC, Terhorst C, High KA, Mingozzi F, Herzog RW.

Blood. 2013 Mar 21;121(12):2224-33. doi: 10.1182/blood-2012-10-460733. Epub 2013 Jan 16.

18.

Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.

Chen M, Maeng K, Nawab A, Francois RA, Bray JK, Reinhard MK, Boye SL, Hauswirth WW, Kaye FJ, Aslanidi G, Srivastava A, Zajac-Kaye M.

Hum Gene Ther Methods. 2017 Feb;28(1):49-59. doi: 10.1089/hgtb.2016.089.

PMID:
28125909
19.

Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.

Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Sun J, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-McKenna M, Hauswirth WW, Boye SL, Boye SE.

PLoS One. 2013 Apr 26;8(4):e62097. doi: 10.1371/journal.pone.0062097. Print 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/99ee1789-a658-4fb0-8593-40a40e9f344a.

20.

Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.

Mowat FM, Gornik KR, Dinculescu A, Boye SL, Hauswirth WW, Petersen-Jones SM, Bartoe JT.

Gene Ther. 2014 Jan;21(1):96-105. doi: 10.1038/gt.2013.64. Epub 2013 Nov 14.

Supplemental Content

Support Center